Cannabinoid treatment for autism: a proof-of-concept randomized trial

Table 3 Common adverse events reported during either 12-week treatment period

	Whole-plant extract CBD 5.5 mg/kg/d; n = 95 (%)	Pure cannabinoids CBD 5.5 mg/kg/d; n = 93 (%)	Placebo n = 94 (%)	P value (placebo vs cannabinoids)
Somnolence	27	24	7.5	< 0.001
Mild	20	18.5	7.5
Moderate	7	5.5	0
Severe	0	0	0
Decreased appetite	24	22	15	0.157
Mild	21	16.5	13
Moderate	3	5.5	2
Severe	0	0	0
Weight loss	12	13	4	0.053
Mild	9	12	3
Moderate	3	1	1
Severe	0	0	0
Tiredness	25	34	19	0.077
Mild	21	28.5	18
Moderate	4	5.5	1
Severe	0	0	0
Euphoria	20	19	13	0.201
Mild	15	16	12
Moderate	5	3	1
Severe	0	0	0
Anxiety	20	27	14	0.084
Mild	17	25	11
Moderate	3	2	3

CBD: cannabidiol (CBD:THC ratio was 20:1 for both cannabinoids tested; the average daily dose per kg was lower than the target dose as many participants weighted over 42 kg and reached the maximal daily dose)
Bold: sum of mild + moderate + severe for each adverse event

ISSN: 2040-2392